secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-07-14T23:59:59+00:00
Accession:  0001615219-25-000069
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius gets additional Nasdaq extension to late July 2025 for equity standard compliance
--------------------------------------------------------------------------------

- Nasdaq Hearings Panel extended deadline to regain Equity Standard compliance to late July 2025.
- Minimum Bid Price Requirement must be met by early August 2025.
- On Jan 13, 2025, Salarius announced a merger agreement with Decoy Therapeutics; combined company to be named Decoy Therapeutics.
- Failure to meet milestones could trigger delisting; previous deadline for equity standard was early July 2025.
- Merger closing conditions remain; Decoy's CEO Rick Pierce will lead combined company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000069/0001615219-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000069/flks-20250710.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer